BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Operating Expenses

The Total Operating Expenses of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 418.80 M CNY. In the previous year, Total Operating Expenses was 406.16 M CNY — a change of 3.11% (higher).

Operating Expenses

418.80 MCNY

YoY

3.11%

Last updated:

Total Operating Expenses of BrightGene Bio-Medical Technology Co is 2025 418.80 M CNY. Total Operating Expenses of BrightGene Bio-Medical Technology Co was 2024 406.16 M CNY. It decreases by 3.11% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Operating Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Operating Expenses
Date
Operating Expenses
Jan 1, 2018
127.04 M CNY
Jan 1, 2019
164.49 M CNY
Jan 1, 2020
188.34 M CNY
Jan 1, 2021
264.06 M CNY
Jan 1, 2022
330.23 M CNY
Jan 1, 2023
348.29 M CNY
Jan 1, 2024
406.16 M CNY
Jan 1, 2025
418.80 M CNY
The BrightGene Bio-Medical Technology Co Operating Expenses history
YEAROperating ExpensesYoY
418.80 MCNY+3.11%
406.16 MCNY+16.61%
348.29 MCNY+5.47%
330.23 MCNY+25.06%
264.06 MCNY+40.20%
188.34 MCNY+14.50%
164.49 MCNY+29.48%
127.04 MCNY-1.09%
128.45 MCNY+34.45%
95.53 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Total Operating Expenses of BrightGene Bio-Medical Technology Co is 418.80 M CNY in 2025.

Total Operating Expenses of BrightGene Bio-Medical Technology Co changed from 406.16 M CNY to 418.80 M CNY, representing a 3.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Operating Expenses BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Operating expenses are the costs incurred in the normal course of business operations, including COGS, SG&A, R&D, and depreciation.

Total Operating Expenses's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Operating Expenses's BrightGene Bio-Medical Technology Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co